Aimovig of Amgen commence robust for migraine treatment
The U.S. Food and Drug Administration (FDA) has given the approval to preventative migraine treatment, Aimovig of Amgen. Aimovig has a price of USD 6,900 per year, but according to analysis of sales, it gives information that migraine treatment is making its way to the front as a preferred treatment. An analysis done by Seeking Alpha, IMS data shows that new patient are going strong for the anti-CGRP treatment. The data showed that 20,000 patients are using the treatment by Seeking Alpha analysis. Also 11,000 patients more are anticipated to commence taking the medication for treatment of their migraines. Aimovig is currently being used by patients, who are “both episodic and chronic migraine patients” and is also being taken by patients who “are on another suboptimal preventive drug.” The treatment was given approval by the FDA after Phase III results indicated the medication decreased monthly migraine attacks to half. The medication is the only FDA-accepted treatment specifically developed to avert migraine by hindering the calcitonin gene-related peptide receptor (CGRP-R). As Amgen likes paving the way in migraine research, the company can also enter in the multiple myeloma market. Amgen released data from its pipeline drug AMG-420, bispecific T cell engager, got acquisition from Boehringer Ingelheim. Data showed five patients treated with AMG-420 indicated strict complete responses in relapsed/refractory multiple myeloma, according to Seeking Alpha. AMG-420 aims B-cell maturation antigen (BCMA), a target in multiple myeloma, due to its constrained expression of normal tissue and uniform expression on multiple myeloma cells. When acquired the treatment from BI, Amgen observed that the modified antibodies from the therapeutics are designed to involve two different targets simultaneously, thus juxtaposing T cells (a type of white blood cell capable of killing other cells that are seemed as threats) to cancer cells. The drug has a long way to go before receiving regulatory approval, and it could become a principal treatment in the multiple myeloma space.